UCB Announces New BIMZELX (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa (€249.70, -1.60)
EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Besponsa ($27.57, 0.00)
UCB announces PrBIMZELX has received positive reimbursement recommendation from INESSS for adults living with moderate to severe hidradenitis suppurativa (€250.80, -3.10)
UCB receives positive CHMP opinion for new ZILBRYSQ (zilucoplan) pre-filled pen in EU for adults living with generalized myasthenia gravis (€253.90, 0.00)
UCB selects Georgia as the location for its new U.S. biologics manufacturing facility (€247.40, 0.00)
HHS/CMS announce full participation by drugmakers in third round of Medicare price negotiations under IRA
StreetAccount Sector Summary - Healthcare Post-Market
StreetAccount Summary - European pre-market trading update
UCB reports positive BE BOLD data as BIMZELX shows superiority over SKYRIZI in PsA (€263.30, 0.00)
StreetAccount Sector Summary - Healthcare Weekly Recap
Powered by FactSet Research Systems Inc.